Making new connections is vital to helping biotechs continue on their commercialization journey. There is no better time for biotech companies to focus on relationship building, and creating connections for both current and future needs. Advanced Therapies Connect is a 2 day, member-only, free, virtual event designed to do just that. Help you to create new connections and with Phacilitate Match program, you will be paired with companies and people that will truly be of value to you and your business.

Meet the experts at Advanced Therapies Connect and attend the free virtual event to listen to our latest advancements in our platforms:


Meet the Experts Session 1:

AAV Suspension Platform Generation with significant Increase in Viral Vector Titer and Yield

The field of gene therapy has experienced significant growth in recent years. Adenoassociated virus (AAV)–mediated therapies account for ~70% of the gene therapy market. However, the manufacturing capacity for AAV vectors remains a critical bottleneck. WuXi Advanced Therapies launched a world-class AAV suspension platform early 2020. In this webinar, we will reveal the improvements that increased viral vector titer and yield on our platform.

The advancements in the platform include:
· Significant increase of viral vector titer
· Increased coverage of AAV serotypes
· Decreased process variability by using chemically defined growth medium
· Optimized and simplified downstream processing
· An increase in integrated testing capacity.

Yiyu Dong, Head of Cell Line Development
David Barnard, Senior Scientist, Process and Technology Development


Meet the Experts Session 2:

Innovative Closed Process CAR-T Cell Therapy Platform: A Streamlined Approach for Manufacturing with Great Predictability

For many years, the primary forms of cancer treatment have been chemotherapy, radiation, and surgery. An amazing breakthrough known as chimeric antigen receptor (CAR) T-cell therapy is being studied in the treatment of various types of cancer, including acute and chronic lymphoblastic leukemia, non-Hodgkin lymphoma, myeloma, and solid tumors. Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Technologies recently announced the expansion of its service capabilities by offering a fully integrated CAR-T cell therapy platform to help accelerate the timeline for cell and gene therapy development, manufacturing, and release while providing greater predictability.

This presentation will showcase a method for accelerating timelines and progress to market for CAR-T production that includes: in-stock raw materials with established batch records; regulatory and technical expertise; process and analytical development; full in-process and release testing; robust quality control and quality assurance oversight; and facilities that offer the capacity and flexibility to meet client timeline needs. The platform also offers a closed process that allows flexibility of clinical manufacturing in a shared pre-equipped suite model that will significantly increase efficiency while mitigating cost.

Key Takeaways:
· How a closed-process CAR-T cell therapy platform streamlines manufacturing
· How to accelerate timelines and progress to market for CAR-T production
· How to mitigate risk with greater predictability through a fully integrated platform

Poonam Sharma, Ph.D., Senior Scientist, Process Development and Commercialization


Meet the Experts Session 3:

Market Demand for High-Quality and Cost-Effective Plasmid Platform

In recent years, the demand for cell and gene therapy has increased substantially. With the success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality Plasmid DNA, key prominent market challenges are capacity availability, accelerated TAT and affordability. In this presentation, WuXi Advanced Therapies will showcase how to address these prominent challenges to provide high-quality, cost-effective and accelerated TAT for GMP like and GMP Plasmid DNA market supply to help accelerate customer’s pipeline to market.

Key Takeaways:
· High-quality and Cost-effective Plasmid DNA Solution
· Flexible Facility with Accelerated TAT
· Capabilities of ATU Plasmid Platform
· WuXi ATU GMP plasmids & Manufacturing Experience

Dr. Shuyuan Yao, Chief Scientific Officer and Head of Research & Technology Development


Free VIP Registration